Understanding how AdipoRon inhibits PDAC cells’ mitochondrial function and energy metabolism, we can now speculate that the low expression of adiponectin in cancer [25–27] as well as the low level of adiponectin-receptor expression in pancreatic cancer [10] could be driven by a metabolic survival adaptation. The gene discussed is ADIPOQ; the disease is pancreatic neoplasm.